A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CDZ173 in Patients With Primary Sjögren's Syndrome

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CDZ173 in Patients With Primary Sjögren's Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Leniolisib (Primary)
  • Indications Sjogren's syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 16 Jun 2018 Primary endpoint (EULAR Sjgrens Syndrome Patient Reported Intensity (ESSPRI) change from baseline) has not been met, according to results presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 08 Jun 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top